Treeline Biosciences
Watertown, US · Founded 2021 · Delaware corporation · 4 known investors
Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research. The company serves cancer patients through drug discovery and development.
AI & Machine LearningBiotechMedical Devices
Founders & leadership
JH
Joshua H. BilenkerExecutive Officer, Director, Promoter
JE
Jeffrey EngelmanExecutive Officer, Director, Promoter
KB
Kristina BurowDirector
AS
Ali SatvatDirector
DS
David SchenkeinDirector
SE
Steven ElmsDirector
DB
David BonitaDirector
AK
Aftab KheraniDirector
AN
Avi NaiderDirector
J
Jeff
Investors · 4
Reported raises · per SEC filings
Form D private placements▶$200.1MraisedSep 2025 · 22 investors · BiotechnologyRule 506(b)
▶$200.1MraisedSep 2025 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven ElmsDirector
- Kristina BurowDirector
- David BonitaDirector
- Joshua H. BilenkerExecutive Officer, Director, Promoter
- Jeffrey EngelmanExecutive Officer, Director, Promoter
- Aftab KheraniDirector
- Ali SatvatDirector
- Avi NaiderDirector
- David SchenkeinDirector
- Offering amount
- $250M
- Amount sold
- $200.1M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$421.8MraisedOct 2024 · 43 investors · BiotechnologyRule 506(b)
▶$421.8MraisedOct 2024 · 43 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joshua H. BilenkerExecutive Officer, Director, Promoter
- Jeffrey EngelmanExecutive Officer, Director, Promoter
- Avi NaiderDirector
- Kristina BurowDirector
- Ali SatvatDirector
- David SchenkeinDirector
- Steven ElmsDirector
- David BonitaDirector
- Aftab KheraniDirector
- Offering amount
- $421.8M
- Amount sold
- $421.8M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$261.3MraisedOct 2022 · 44 investors · BiotechnologyRule 506(b)
▶$261.3MraisedOct 2022 · 44 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ali SatvatDirector
- Avi NaiderDirector
- Kristina BurowDirector
- David SchenkeinDirector
- Jeffrey EngelmanExecutive Officer, Director, Promoter
- Joshua H. BilenkerExecutive Officer, Director, Promoter
- David BonitaDirector
- Aftab KheraniDirector
- Steven ElmsDirector
- Offering amount
- $269.3M
- Amount sold
- $261.3M
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$211.7MraisedApr 2021 · 34 investors · BiotechnologyRule 506(b)
▶$211.7MraisedApr 2021 · 34 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
- Steven ElmsDirector
- Avi NaiderDirector
- Aftab KheraniDirector
- David BonitaDirector
- Kristina BurowDirector
- Joshua H. BilenkerExecutive Officer, Director, Promoter
- Jeffrey EngelmanExecutive Officer, Director, Promoter
- David SchenkeinDirector
- Offering amount
- $220M
- Amount sold
- $211.7M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Neumora's Phase 3 Trial Miss and a Trio of VC Raises — Watertown Biowatertown.bio · 2026
- Treeline Raises $200M in Additional Fundingfinsmes.com · 2025
- Treeline reaps $200M series A extension, plucks first 3 clinical candidatesfiercebiotech.com · 2025
- Startup Treeline Bio Emerges From the Shadows With $1B+ Raised and 3 Cancer Drugs in the Clinic - MedCity Newsmedcitynews.com · 2025
- Treeline Biosciences: $200 Million Additional Funding Raised And First Clinical Trials Announcedpulse2.com · 2025
- Treeline Biosciences raises $200M, enters clinical trials - Boston Business Journalbizjournals.com · 2025
- Treeline Biosciences closed their Series Atreelinebiosciences.com · 2021